Double maintains 3 strategies that include VKTX - Viking Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 58.69% | $4.85B | 0.35% |
IBB | 49.37% | $5.22B | 0.45% |
PBE | 49.09% | $214.12M | 0.58% |
PINK | 45.18% | $131.52M | 0.5% |
GNOM | 44.79% | $40.65M | 0.5% |
FBT | 44.56% | $994.71M | 0.56% |
BBH | 42.19% | $327.42M | 0.35% |
PTH | 42.05% | $96.56M | 0.6% |
IWC | 42.00% | $766.88M | 0.6% |
SECT | 41.64% | $1.98B | 0.78% |
IWO | 41.62% | $11.36B | 0.24% |
VBK | 41.08% | $18.33B | 0.07% |
ARKG | 40.83% | $944.78M | 0.75% |
XPH | 40.72% | $136.58M | 0.35% |
IHAK | 40.37% | $921.20M | 0.47% |
ROBT | 40.35% | $462.06M | 0.65% |
VXF | 40.26% | $21.56B | 0.05% |
TECB | 40.20% | $417.43M | 0.3% |
QQQJ | 40.13% | $610.08M | 0.15% |
FXL | 40.05% | $1.31B | 0.62% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -32.92% | $140.49M | 0.59% |
VIXY | -29.97% | $109.64M | 0.85% |
BTAL | -29.52% | $361.41M | 1.43% |
FTSD | -16.52% | $212.46M | 0.25% |
IVOL | -14.01% | $353.94M | 1.02% |
IBTG | -13.95% | $1.88B | 0.07% |
FXY | -11.00% | $838.61M | 0.4% |
XONE | -10.35% | $603.24M | 0.03% |
SPTS | -9.74% | $5.76B | 0.03% |
SCHO | -9.54% | $10.87B | 0.03% |
AGZ | -8.63% | $607.46M | 0.2% |
ULST | -8.33% | $637.77M | 0.2% |
UTWO | -8.29% | $387.71M | 0.15% |
CARY | -7.78% | $347.36M | 0.8% |
VGSH | -6.99% | $22.38B | 0.03% |
IBTH | -6.83% | $1.53B | 0.07% |
LGOV | -6.63% | $684.47M | 0.67% |
IBTI | -6.37% | $995.39M | 0.07% |
STXT | -6.28% | $134.15M | 0.49% |
IBTJ | -5.35% | $658.04M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRYS | 45.82% | $3.77B | -20.42% | 0.00% |
CRNX | 45.18% | $2.92B | -39.88% | 0.00% |
ALT | 44.67% | $468.80M | -35.06% | 0.00% |
ROIV | 44.42% | $7.68B | -5.70% | 0.00% |
CIGI | 43.50% | $6.48B | +9.79% | 0.23% |
OCUL | 42.38% | $1.14B | +14.35% | 0.00% |
PLXS | 42.37% | $3.59B | +21.88% | 0.00% |
WH | 41.96% | $6.61B | +20.29% | 1.80% |
LGND | 41.86% | $2.00B | +21.70% | 0.00% |
DNLI | 41.53% | $2.06B | -30.04% | 0.00% |
APGE | 41.14% | $2.42B | -24.39% | 0.00% |
CLDX | 40.74% | $1.33B | -49.67% | 0.00% |
XENE | 40.12% | $2.27B | -26.70% | 0.00% |
CBRE | 40.09% | $38.83B | +41.52% | 0.00% |
GPCR | 39.83% | $1.41B | -31.91% | 0.00% |
NOW | 39.68% | $214.28B | +36.57% | 0.00% |
TYL | 39.18% | $24.70B | +17.37% | 0.00% |
XNCR | 38.94% | $583.60M | -63.49% | 0.00% |
ATXS | 38.91% | $225.17M | -57.69% | 0.00% |
BELFB | 38.74% | $960.65M | +17.20% | 0.36% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EDV | 0.02% | $3.32B | 0.05% |
TLT | 0.07% | $47.60B | 0.15% |
JBND | -0.13% | $1.92B | 0.25% |
GVI | 0.18% | $3.37B | 0.2% |
NUBD | -0.21% | $388.33M | 0.16% |
TLH | 0.21% | $9.85B | 0.15% |
FLMI | 0.22% | $649.76M | 0.3% |
WEAT | -0.24% | $115.83M | 0.28% |
SPTL | -0.29% | $10.96B | 0.03% |
UUP | 0.30% | $292.27M | 0.77% |
IBMN | 0.34% | $446.12M | 0.18% |
ZROZ | -0.38% | $1.44B | 0.15% |
BWX | -0.41% | $1.41B | 0.35% |
SMB | 0.46% | $269.10M | 0.07% |
UDN | 0.58% | $137.74M | 0.78% |
VGLT | -0.58% | $9.57B | 0.04% |
FLCB | 0.64% | $2.52B | 0.15% |
UNG | 0.64% | $371.83M | 1.06% |
LDUR | 0.73% | $849.09M | 0.5% |
MEAR | 0.74% | $1.03B | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ROL | -16.04% | $27.32B | +19.76% | 1.14% |
EW | -15.85% | $45.10B | -14.68% | 0.00% |
FMTO | -9.56% | $45.74M | -99.96% | 0.00% |
PULM | -9.38% | $23.82M | +239.64% | 0.00% |
HIHO | -7.73% | $8.25M | -10.29% | 3.73% |
PM | -7.72% | $263.27B | +68.03% | 3.17% |
WM | -7.55% | $91.76B | +7.46% | 1.35% |
EXC | -7.43% | $43.84B | +12.45% | 3.59% |
HEES | -7.33% | $3.52B | +99.54% | 1.15% |
YORW | -6.71% | $469.88M | -15.42% | 2.64% |
CME | -6.62% | $98.74B | +28.80% | 3.84% |
LKQ | -6.12% | $10.87B | -4.60% | 3.54% |
WTRG | -5.93% | $10.70B | -3.17% | 3.41% |
MO | -5.77% | $97.80B | +26.35% | 6.94% |
CHD | -5.63% | $23.29B | -11.36% | 1.23% |
AWK | -5.40% | $27.37B | +4.54% | 2.22% |
MSEX | -5.30% | $1.02B | -1.01% | 2.34% |
CBOE | -5.22% | $22.95B | +20.67% | 1.12% |
PRA | -4.73% | $1.19B | +58.17% | 0.00% |
IMNN | -4.52% | $8.21M | -59.89% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KDP | -0.06% | $45.55B | -1.76% | 2.70% |
NEM | 0.08% | $55.47B | +16.34% | 2.04% |
WBA | 0.09% | $9.67B | -39.04% | 6.69% |
VZ | 0.09% | $183.32B | +8.02% | 6.21% |
TSN | 0.09% | $19.43B | -8.67% | 3.56% |
CMS | -0.10% | $21.21B | +12.27% | 2.97% |
TKC | 0.11% | $5.49B | -3.37% | 3.28% |
RSG | -0.16% | $76.55B | +30.51% | 0.93% |
HSY | -0.22% | $33.16B | -21.37% | 3.44% |
VSTA | 0.24% | $326.82M | +11.64% | 0.00% |
GFI | 0.37% | $18.61B | +31.67% | 2.75% |
VHC | -0.51% | $34.69M | +74.89% | 0.00% |
MSIF | -0.58% | $715.25M | +28.42% | 7.05% |
KR | -0.59% | $44.68B | +24.17% | 1.89% |
IMRN | 0.60% | $9.97M | -25.82% | 0.00% |
AIFU | -0.64% | $9.85M | -95.03% | 0.00% |
NEOG | -0.64% | $1.42B | -51.08% | 0.00% |
INVH | -0.66% | $20.86B | -3.35% | 3.35% |
UUU | 0.78% | $4.93M | +40.20% | 0.00% |
FE | 0.84% | $24.49B | +5.52% | 4.06% |
Yahoo
Viking is pushing hard in its development of a weight-loss drug. A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. This is the Denmark-based pharmaceutical company that vaulted to prominence earlier this decade when its Wegovy became the first GLP-1 drug approved for obesity by the U.S. Food and Drug Administration (FDA).
SeekingAlpha
Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.
SeekingAlpha
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Yahoo
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Yahoo
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Yahoo
Viking Therapeutics has a promising pipeline candidate in the fast-growing therapeutic area of weight loss. Madrigal Pharmaceuticals markets the only approved therapy for a disease whose prevalence is growing. Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns.
Current Value
$27.891 Year Return
Current Value
$27.891 Year Return